FDA
-
-
-
-
-
-
-
Vertex to Acquire Crinetics Pharmaceuticals
-
-
-
-
-
-
-
Vertex gets FDA acceptance for IgA nephropathy drug application
-
-
-
-
-
-
-
Vertex gets FDA approval to expand ALYFTREK and TRIKAFTA to 95% of US CF patients
-
-
-
-
-
-
-
Vertex Reports Fourth Quarter and Full Year 2025 Financial Results
-
-
-
-
-
-
-
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
-
-
-
-
-
-
-
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
-
-
-
-
-
-
-
Vertex (VRTX) PT Lowered to $411 at Canaccord Genuity
-
330,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

